Stock Snapshot from
Supernus Pharmaceuticals IncAdd to My Watchlist
SUPN:USNASDAQ GMIndustry: Medical-Drugs
- 6.00Last
- 0.16 2.74%Today's Change
- 5.84Previous Close
- 52 Week Low - High
Earnings
| EPS: Year Actual ttm | -2.270 |
| EPS: Year Est. 12/13 ttm | -2.463 |
| EPS: Quarterly Actual 3/13 | -0.60 |
| EPS: Quarterly Est. 6/13 | -0.66 |
| Price/Earnings ttm | -- |
| Relative Price/Earnings | -- |
| Earnings Growth Rate | 34.46 |
Company Description
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus has developed a portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson's disease, ADHD, depression and anxiety. | |
| Revenue | $1 million |
| Net Income | $-46 million |
| Total Assets | $94 million |
| Employees | 110 |
| Web Site | www.supernus.com |
Latest Headlines
No news available.
Watchlist
Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.